Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996374 | 0.81 | SLC7A5 (0.57) | SLC7A5LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4889896 | 0.81 | SLC7A5 (0.57) | SLC7A5LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11381732 | 0.80 | ENPEP (0.39) | ENPEP | |
| SCHEMBL11381735 | 0.80 | ENPEP (0.39) | ENPEP | |
| SCHEMBL15390916 | 0.77 | SLC7A5 (0.39) | ENPEPSLC7A5LTA4HSLC1A3SLC1A2 | |
| SCHEMBL1852419 | 0.77 | SLC7A5 (0.39) | ENPEPSLC7A5LTA4HSLC1A3SLC1A2 | |
| SCHEMBL7447974 | 0.77 | PTGS1 (0.45) | PTGS1SLC7A11ENPEPSLC7A5SLC1A3 | |
| SCHEMBL4633868 | 0.74 | — | — | |
| SCHEMBL4586401 | 0.74 | — | — | |
| Cysteine SCHEMBL5573292 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | PTGS1 1171/4885SLC7A11 3801/4885ENPEP 63/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | PTGS1 1171/4885SLC7A11 3801/4885ENPEP 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.